{"id":"NCT02319642","sponsor":"UCB Pharma SA","briefTitle":"An Open-label Extension Study of Certolizumab Pegol in Chinese Patients With Rheumatoid Arthritis Who Enrolled in RA0044","officialTitle":"A Phase 3, Multicenter, Open-label Extension Study To Assess The Safety And Efficacy Of Certolizumab Pegol As Additional Medication To Methotrexate In Chinese Subjects With Active Rheumatoid Arthritis Who Participated In RA0044.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-11","primaryCompletion":"2016-12","completion":"2016-12","firstPosted":"2014-12-18","resultsPosted":"2018-10-16","lastUpdate":"2018-10-16"},"enrollment":347,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"Certolizumab Pegol","otherNames":["Cimzia"]}],"arms":[{"label":"Certolizumab Pegol (CZP)","type":"EXPERIMENTAL"}],"summary":"This study will continue to evaluate the safety \\& efficacy of Certolizumab Pegol (CZP) for 6 months in Chinese subjects with active Rheumatoid Arthritis who participated in RA0044.","primaryOutcome":{"measure":"Percentage of Subjects That Withdrew Due to a Treatment-emergent Adverse Event (TEAE)","timeFrame":"Baseline to the end of observation period (32 weeks)","effectByArm":[{"arm":"Open-label Cimzia (Placebo in Feeder Study)","deltaMin":2.1,"sd":null},{"arm":"Open-label Cimzia (Cimzia in Feeder Study)","deltaMin":1.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":21},"locations":{"siteCount":30,"countries":["China"]},"refs":{"pmids":[],"seeAlso":["http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":95},"commonTop":["Upper respiratory tract infection","Anaemia","Liver function test abnormal"]}}